Patent ID: 9494589
Filing Date: 2016-11-15
CPC Classification: A61K,A61P,C12Q,C12Y,G01N,G16B

Claim Text:
1. A method of determining whether a subject having a disease or disorder having an etiology associated with excessive cell proliferation should be treated with a cardiac glycoside, the method comprising: providing or assembling a kit comprising at least the following components: a) a first primary antibody having a binding affinity for the α3 subunit isoform of Na, K-ATPase; and b) a second primary antibody having a binding affinity for the α-1 subunit isoform of Na, K-ATPase; obtaining a sample of tissue from the subject, the tissue exhibiting a disease or disorder having an etiology associated with excessive cell proliferation, the sample comprising one or more isoforms of the αsubunit of Na, K-ATPase; with the kit, determining the ratio of α3 isoform to α1 isoform of Na, K-ATPase α-subunit in the sample, wherein the step of determining the ratio comprises: a) quantifying the level of expression of each the α3 subunit isoform of Na, K-ATPase and the α1 subunit isoform of Na, K-ATPase in the sample, and calculating the ratio thereof; or b) determining the amount of the α3 subunit isoform of Na, K-ATPase relative to amount of the α1 subunit isoform of Na, K-ATPase in the sample, and calculating the ratio thereof; and if the ratio is ≧0.3, indicating the subject should be treated with cardiac glycoside by administration of a composition comprising cardiac glycoside to the subject, or if the ratio is <0.3, indicating the subject should not be treated with cardiac glycoside for treatment of the disease or disorder having an etiology associated with excessive cell proliferation.